Digital therapeutics

Digital Therapeutics (DTx) Market Report 2022: Increasing Demand for Digital Delivery of Behavioral Therapy Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 23, 2022
Health, Health Technology, MSD, Investment, Prevalence, Patient, Central nervous system disease, CRD, Digital, Medicine, Degenerative disease, Chronic Respiratory Disease, Government, Single-frequency network, Substance Abuse, Diabetes, GI, CNS, USD, CVD, Digital therapeutics, Therapy, Growth, Conditional sentence, Direct-to-consumer, Smoking cessation, Providers, Health, Sales, Pharmaceutical industry, Pharma, Rehabilitation

The adoption of digital therapeutics is growing at a fast pace owing to factors such as the rise in the number of patients with chronic diseases and growing investments in digital therapeutics.

Key Points: 
  • The adoption of digital therapeutics is growing at a fast pace owing to factors such as the rise in the number of patients with chronic diseases and growing investments in digital therapeutics.
  • On the basis of application, the digital therapeutics market is divided into preventive and treatment/care-related applications.
  • On the basis of sales channels, the digital therapeutics market is divided into business-to-customer (B2C) and business-to-business (B2B).
  • Factors such as the improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform

Retrieved on: 
Monday, November 14, 2022
Data Management, Health, Technology, Software, General Health, Pharmaceutical, Biotechnology, FDA, Investment, Medication, Failure, Senior, Teva Pharmaceuticals, Digital, NYSE, Biosimilar, Medicine, Aggregation, TASE, Research, Electronic health record, Asthma, EHR, TEVA, Annual report, Digital therapeutics, Therapy, Ecosystem, Organization, COVID-19, EMR, Travel, Hope, Health, Digital health, Patient, Pharmaceutical industry, Teva

The collaboration will enable healthcare providers to better integrate patient data into their workflows, supporting proactive remote care across large populations.

Key Points: 
  • The collaboration will enable healthcare providers to better integrate patient data into their workflows, supporting proactive remote care across large populations.
  • The platform can be used to monitor and manage large populations by a network of health systems.
  • Digital health platforms will succeed only by seamlessly integrating multiple data sources into workflows and systems like electronic medical records (EMR).
  • We believe in building an ecosystem and are delighted to partner with Rimidi as we seek to expand the reach of our platform, and continue to shape digital therapeutics and the integrated care landscape, said Manny Montalvo, Senior Vice President, Head of Digital Health & Innovation at Teva.

DTA Welcomes Board of Directors for 2023

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Chair, Leadership, Single-frequency network, Digital therapeutics, WELT, Adoption, Board, Therapy, DTA, Entrepreneurship, Growth, CEO, Industry, Board of directors, Management, Alliance

Arlington, VA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Today, the Digital Therapeutics Alliance (DTA), is pleased to announce the results of the 2023 DTA Board of Directors election.

Key Points: 
  • Arlington, VA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Today, the Digital Therapeutics Alliance (DTA), is pleased to announce the results of the 2023 DTA Board of Directors election.
  • With two seats up for election this cycle, DTA members selected Danny Kim, Head of WELT USA, as a new board member and re-elected Owen McCarthy, Co-Founder and President of MedRhythms, Inc. and current Chair to serve on the Board.
  • The 2023 DTA Board of Directors:
    Everett Crosland Chief Commercial Officer, Cognito Therapeutics
    Anand Iyer Chief Strategy Officer, Welldoc
    Eddie Martucci Co-Founder and CEO, Akili Interactive
    Owen McCarthy President and Co-Founder, MedRhythms
    Debra Reisenthel Founding CEO and Board Member, Freespira, Inc.
    Julia Strandberg Chief Commercial Officer, Pear Therapeutics, Inc.
    Andy Molnar Chief Executive Officer, Digital Therapeutics Alliance
    The Board of Directors supports DTAs work to transform global healthcare by advancing digital therapeutics (DTx) and provides critical guidance related to the strategy and direction of the organization.
  • I am excited to work with my fellow directors to pursue our strategic focus in 2023 on advancing adoption and integration of digital therapeutics on a global scale."

Evercore ISI and Digital Therapeutics Alliance to Host DTx Leaders at HLTH 2022

Retrieved on: 
Thursday, November 10, 2022
Professional Services, Health, Other Professional Services, Health Technology, Finance, Banking, NYSE, Single-frequency network, Digital therapeutics, Research, Health, Adoption, Digital, Therapy, EVR, DTA, PST, Program, Awareness, CEO, Pharmaceutical industry, Industry

Evercore (NYSE: EVR) and the Digital Therapeutics Alliance (DTA) will co-host a program on digital therapeutics November 13-16 in Las Vegas at HLTH 2022, presented by HLTH, the leading platform bringing together the health ecosystem.

Key Points: 
  • Evercore (NYSE: EVR) and the Digital Therapeutics Alliance (DTA) will co-host a program on digital therapeutics November 13-16 in Las Vegas at HLTH 2022, presented by HLTH, the leading platform bringing together the health ecosystem.
  • The program, Digital Therapeutics: An Industry is Growing Up & Breaking Out!, is set for 10 a.m.-1 p.m. PST on Sunday, November 13, at the Venetian Expo in Las Vegas.
  • Digital therapeutics, now several years in, continues to prove to be the new innovative chapter for patient care, said Elizabeth Anderson, Evercore ISIs Healthcare Technology & Distribution analyst.
  • Andy Molnar, CEO of DTA, said, We are thrilled to partner with Evercore at HLTH to explore the latest trends and topics in digital therapeutics with industry trailblazers from the Digital Therapeutics Alliance community.

State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, General Health, FDA, Health, Pharmaceutical, Health, FDA, Population, Pharmacoeconomics, Speech disorder, Policy by press release, DOI, BA, PDT, Substance abuse, Treatment, Buprenorphine, Comparison, Journal, Reading, Current Medical Research and Opinion, Substance use disorder, Language isolate, Wisconsin Department of Health Services, Pear, Williams–Campbell syndrome, Postgraduate Medicine, Safety, SUD, ClinicoEconomics and Outcomes Research, OUD, MBA, Cognitive behavioral therapy, Doctor of Philosophy, Insomnia, PEAR, Policy, Digital, Hospital Practice, Journal of Medical Economics, Digital therapeutics, Initiation, DHS, Smartphone, Randomized controlled trial, Therapy, Suicidal ideation, Reset, Risk, Opioid use disorder, MD, Pharmaceutical industry, Birth control, Hospital, Mobile phone, Medical device, Health insurance, Patient, Nasdaq

Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.

Key Points: 
  • Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.
  • The state of Wisconsin is making a difference for those struggling with addiction by expanding access to evidence-based treatment and recovery services, said Julia Strandberg, Chief Commercial Officer of Pear Therapeutics.
  • Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic.
  • Evaluation of real-world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders.

CureApp: Digital Therapeutic App for Hypertension Receives Insurance Coverage, Sales of the Service to Medical Institutions Across Japan Launch on September 1

Retrieved on: 
Wednesday, November 2, 2022
Technology, Mobile, Wireless, Health, Apps, Applications, Research, Telemedicine, Virtual Medicine, Medical Devices, Software, Managed Care, Hospitals, Health Technology, Health Insurance, Science, Clinical Trials, Breast cancer, EHJ, Digital therapeutics, Research, Time, Prescription, SANKYO, Head, Randomized controlled trial, HT, Insurance, Government, Safety, Behavior, PMID, Guideline, Chūō-ku, Education, Health education, Digital, Company, Woman, Patient, Single-frequency network, Medtech, Multimedia, Nicotine, Smoking, Therapy, National Healthcare, Pharmaceutical industry, Medical device, Hypertension

Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.

Key Points: 
  • Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.
  • In April 2022, CureApp HT was the first digital therapeutics app for hypertension to receive government approval in the world, and the app has been covered by insurance since September 1.
  • This marks the first case of a DTx treatment solution being covered by insurance in the field of hypertension in the world.
  • Looking ahead, we will look to sequentially rolling out this Japanese-developed digital health solution worldwide based on the model established in Japan.

+850 Health Innovators Reunited in Milan, Italy, to Shape the Future of Health at Frontiers Health Global Conference 2022

Retrieved on: 
Thursday, October 27, 2022
General Health, Health, Health Technology, Telemedicine, Virtual Medicine, Health Insurance, Health, Medicine, Committee, Frontier Conference, Chronic pain, Ecosystem, Digital health, Frontiers, VR, Insurance, Adoption, DTA, Industry, Technology, Therapy, Patient, Investment, Grey Literature International Steering Committee, CEO, Program, Global, Conference, Multimedia, Digital therapeutics, Video game, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20221026005839/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221026005839/en/
    Frontiers Health Global Conference 2022 (Photo: Frontiers Health)
    The conference celebrated its seventh edition, being recognized as one of the leading international events on health innovation, with a strong focus on topics such as digital transformation, innovative technologies, digital therapies, investments, and ecosystem development.
  • Conference Chairman Roberto Ascione, CEO of the event co-host Healthware Group , shared some insights just after the event:
    I believe at Frontiers Health 2022 we have started to see the beginning of a phase 2 of sorts in digital health.
  • It is a spin-off event of Frontiers Conferences, which designs and produces international conferences about technology and innovation since 2005.
  • Frontiers Health is chaired by Roberto Ascione, CEO of Healthware Group, event co-host.

PRIVATE SALE OF EPILLO TOKEN TO GO LIVE ON 3O OCTOBER, 2022 AT 12 PM GMT

Retrieved on: 
Thursday, October 27, 2022
Ethereum, Bitcoin, Health, Digital, Health care, Medicine, Drink, Polygon, Efficiency, Ecosystem, Electronic health record, Digital health, Sale, Internet, Investment, Solution, Industry, Non-fungible token, Technology, AdeS, IOT, NFT, Method, Burn, Intellectual property, Artificial intelligence, Research, Genomics, Semantic Web, WIPO, Patent, Running, Digital therapeutics, Dynamic systems development method, Cryptocurrency, Pharmaceutical industry, Online shopping, Amusement arcade, Blockchain, Pharmacy

On October 30th 2022, the company will offer an exclusive early bird sale of the EPILLO token.

Key Points: 
  • On October 30th 2022, the company will offer an exclusive early bird sale of the EPILLO token.
  • Epillo Health Token (EPILLO) is the native token of Epillo Health Systems.
  • The first pre-sale of the EPILLO token will begin on "October 30th, 2022 at 12 PM GMT".
  • Once the private and public sale finishes, the company will initiate the listing on exchanges in December 2022 and simultaneously the Token Generation Event will take place.

PRIVATE SALE OF EPILLO TOKEN TO GO LIVE ON 3O OCTOBER, 2022 AT 12 PM GMT

Retrieved on: 
Thursday, October 27, 2022
Ethereum, Bitcoin, Health, Digital, Health care, Medicine, Drink, Polygon, Efficiency, Ecosystem, Electronic health record, Digital health, Sale, Internet, Investment, Solution, Industry, Non-fungible token, Technology, AdeS, IOT, NFT, Method, Burn, Intellectual property, Artificial intelligence, Research, Genomics, Multimedia, Semantic Web, WIPO, Patent, Running, Digital therapeutics, Dynamic systems development method, Cryptocurrency, Pharmaceutical industry, Online shopping, Amusement arcade, Blockchain, Pharmacy

On October 30th 2022, the company will offer an exclusive early bird sale of the EPILLO token.

Key Points: 
  • On October 30th 2022, the company will offer an exclusive early bird sale of the EPILLO token.
  • Epillo Health Token (EPILLO) is the native token of Epillo Health Systems.
  • The first pre-sale of the EPILLO token will begin on "October 30th, 2022 at 12 PM GMT".
  • Once the private and public sale finishes, the company will initiate the listing on exchanges in December 2022 and simultaneously the Token Generation Event will take place.

Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®

Retrieved on: 
Monday, October 24, 2022
Health, General Health, Therapy, Cognitive behavioral therapy, Smartphone, Publication, Treatment, Reading, Williams–Campbell syndrome, Journal, Randomized controlled trial, Safety, Policy, Cannabis, Substance abuse, Population, Policy by press release, Health, Reset, Substance use disorder, MBA, Opioid use disorder, Pear, American Journal, Postgraduate Medicine, Digital, FDA, Current Medical Research and Opinion, Risk, Insomnia, Initiation, Digital therapeutics, Comparison, The American Journal on Addictions, Pharmacoeconomics, Buprenorphine, PDT, Hospital Practice, NIDA, OUD, SUD, Cocaine, PEAR, Efficacy, MD, Doctor of Philosophy, Suicidal ideation, BA, Language isolate, ClinicoEconomics and Outcomes Research, DOI, AJA, Journal of Medical Economics, Pharmaceutical industry, Birth control, Hospital, Mobile phone, Medical device, Health insurance, Nasdaq, Patient

reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Key Points: 
  • reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).
  • Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information.
  • Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population.
  • Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).